Literature DB >> 8590307

Expression of a human mutant monocyte chemotactic protein 3 in Pichia pastoris and characterization as an MCP-3 receptor antagonist.

S Masure1, L Paemen, P Proost, J Van Damme, G Opdenakker.   

Abstract

The cDNA encoding human monocyte chemotactic protein 3 (hMCP-3) was cloned in pHIL-S1, a vector designed for inducible secreted heterologous expression in the methylotrophic yeast Pichia pastoris. After transformation of P. pastoris by electroporation, several clones with the human MCP-3 gene integrated at the alcohol oxidase (AOX-1) locus were isolated. One of these clones (M30) expressed the mature MCP-3 protein with three additional amino acids at its NH2 terminus as a secretion product in the supernatant. The recombinant protein comigrated on SDS-PAGE and cross-reacted immunologically with synthetic hMCP-3. Intermediate-scale production in shake flasks was obtained at expression levels of approximately 1 mg per liter. The recombinant mutant MCP-3 was purified to homogeneity by adsorption on silicic acid, affinity chromatography on heparin-Sepharose, and reversed-phase HPLC. At the amino terminus of the purified recombinant protein, the presence of the additional sequence Arg-Glu-Phe was confirmed by direct protein sequence analysis. The recombinant hMCP-3 mutein was not glycosylated, as evidenced by deglycosylation experiments and by mass spectrometry. In analogy with MCP-1, the amino terminus of MCP-3 is crucial for its agonistic effect on receptive cells. At concentrations up to 3.5 micrograms/ml, the recombinant mutein was not active in vitro as a chemotactic factor for monocytes. However, the mutant MCP-3 acted as an MCP-3 receptor antagonist in a competition chemotaxis assay at 100- to 1000-fold excess over the synthetic MCP-3 agonist. It might thus be a useful tool to study antagonism of MCP-3 action in vitro and in disease models of cancer and inflammation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590307     DOI: 10.1089/jir.1995.15.955

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  6 in total

Review 1.  Recombinant protein expression in Pichia pastoris.

Authors:  J M Cregg; J L Cereghino; J Shi; D R Higgins
Journal:  Mol Biotechnol       Date:  2000-09       Impact factor: 2.860

2.  The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions.

Authors:  Holger Cynis; Torsten Hoffmann; Daniel Friedrich; Astrid Kehlen; Kathrin Gans; Martin Kleinschmidt; Jens-Ulrich Rahfeld; Raik Wolf; Michael Wermann; Anett Stephan; Monique Haegele; Reinhard Sedlmeier; Sigrid Graubner; Wolfgang Jagla; Anke Müller; Rico Eichentopf; Ulrich Heiser; Franziska Seifert; Paul H A Quax; Margreet R de Vries; Isabel Hesse; Daniela Trautwein; Ulrich Wollert; Sabine Berg; Ernst-Joachim Freyse; Stephan Schilling; Hans-Ulrich Demuth
Journal:  EMBO Mol Med       Date:  2011-07-20       Impact factor: 12.137

3.  Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.

Authors:  D Schols; S Struyf; J Van Damme; J A Esté; G Henson; E De Clercq
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

Review 4.  Blocking chemokine receptors.

Authors:  M Baggiolini; B Moser
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

5.  Crucial biological functions of CCL7 in cancer.

Authors:  Yangyang Liu; Yadi Cai; Li Liu; Yudong Wu; Xiangyang Xiong
Journal:  PeerJ       Date:  2018-06-14       Impact factor: 2.984

6.  A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.

Authors:  Fabrice Cerini; Hubert Gaertner; Knut Madden; Ilya Tolstorukov; Scott Brown; Bram Laukens; Nico Callewaert; Jay C Harner; Anna M Oommen; John T Harms; Anthony R Sump; Robert C Sealock; Dustin J Peterson; Scott K Johnson; Stephan B Abramson; Michael Meagher; Robin Offord; Oliver Hartley
Journal:  Protein Expr Purif       Date:  2015-10-24       Impact factor: 1.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.